powered by centersite dot net
Medications
Resources
Basic InformationLatest News
Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly DrugsPrices Skyrocket on Drugs Widely Used by Seniors: Report1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyU.S. Doctors Still Over-Prescribing Drugs: SurveyWider Low-Dose Aspirin Use Would Save U.S. $692 Billion: StudyHealth Tip: Get the Facts About AntibioticsThese Medicines Often Send Americans to ERsHealth Tip: Be Aware of Drug and Food InteractionsCan Time-Release Capsules Replace Daily Pills?Prices of Generic Heart Failure Drugs Vary WidelyAmericans Fed Up With Soaring Drug Prices: HealthDay/Harris PollSaturday, Oct. 22 Is Drug Take Back DayHow Older People Can Head Off Dangerous Drug InteractionsCDC: Too Many Antibiotics Still Being Prescribed in U.S.Codeine Not Safe for Kids, Pediatricians WarnHealth Tip: Reading the Label on OTC MedicationsMylan to Offer Generic EpiPenSteep Rise in U.S. Drug Prices Tied to Patent MonopoliesSpending on Compounded Drugs Skyrocketing
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Outcomes-Based Pricing Suggested for New, Costly Drugs


HealthDay News
Updated: Dec 14th 2016

new article illustration

WEDNESDAY, Dec. 14, 2016 (HealthDay News) -- Outcomes-based pricing for novel and expensive biopharmaceuticals is supported in an Ideas and Opinions piece published online Dec. 13 in the Annals of Internal Medicine.

Daniel M. Blumenthal, M.D., from Massachusetts General Hospital in Boston, and colleagues discuss the importance of new pricing models for insurers and manufacturers of biopharmaceuticals. They used the example of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

The authors note that PCSK9 inhibitors pose two hurdles to insurers and patients: their cost (estimated at $10,000 to $15,000 annually) and their ultimate efficacy. Insurers have implemented traditional utilization management tools such as step therapy and prior authorization in order to limit their use, meaning that uptake of PCSK9 inhibitors has been slow. In order to provide treatment access at a reasonable cost, outcomes-based pricing can be used. This method relies on real-world clinical outcomes to determine efficacy of drugs and their price. Discounts could be offered by manufacturers with additional payment triggered by prospectively observed clinical end points; insurers could add preferential formulary placement and discontinue utilization management. Outcomes-based pricing obliges manufacturers and insurers to share the risks and rewards associated with treatment failure and success.

"Outcomes-based pricing, a drug-pricing approach grounded in real-world outcomes, would compel manufacturers and insurers to share accountability for clinical outcomes and ensure that we pay for health, not health care," the authors write.

The authors disclosed ties to Precision Health Economics, which provides consulting services to the life sciences industry.

Full Text (subscription or payment may be required)